Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Gerstner

Showing results (101-110 of 133) with videos related to

Pageof 14
Sort By:
Neuro-Oncology|October 11, 2017
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02Evanthia Galanis, S Keith Anderson, C Ryan Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsBenjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
Nature Biomedical Engineering|April 6, 2019
Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithiumGiorgio Seano, Hadi T Nia, Kyrre E Emblem, et al.
Neuro-Oncology Advances|February 8, 2023
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastomaAndrea Schmidts, Ambike A Srivastava, Rishab Ramapriyan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed GlioblastomaMary Jane Lim-Fat, J Bryan Iorgulescu, Rifaquat Rahman, et al.
Neuro-Oncology Advances|April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomasShuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Neuro-Oncology|December 15, 2025
Tumor-Infiltrating Lymphocyte Therapy Generated from Melanoma Brain Metastasis: Proof-of-Concept for CNS-Derived Cellular ImmunotherapyEric P Grewal, Samuel J Steuart, Baolin Liu, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2023
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent GlioblastomaGilbert Youssef, Rifaquat Rahman, Camden Bay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2023
Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma PatientsK Ina Ly, Leland G Richardson, Mofei Liu, et al.
Pageof 14

Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Neuro-Oncology|October 11, 2017
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02Evanthia Galanis, S Keith Anderson, C Ryan Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsBenjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
Nature Biomedical Engineering|April 6, 2019
Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithiumGiorgio Seano, Hadi T Nia, Kyrre E Emblem, et al.
Neuro-Oncology Advances|February 8, 2023
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastomaAndrea Schmidts, Ambike A Srivastava, Rishab Ramapriyan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed GlioblastomaMary Jane Lim-Fat, J Bryan Iorgulescu, Rifaquat Rahman, et al.
Neuro-Oncology Advances|April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomasShuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Neuro-Oncology|December 15, 2025
Tumor-Infiltrating Lymphocyte Therapy Generated from Melanoma Brain Metastasis: Proof-of-Concept for CNS-Derived Cellular ImmunotherapyEric P Grewal, Samuel J Steuart, Baolin Liu, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2023
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent GlioblastomaGilbert Youssef, Rifaquat Rahman, Camden Bay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2023
Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma PatientsK Ina Ly, Leland G Richardson, Mofei Liu, et al.
Pageof 14